Last updated 56 days ago
Empagliflozin for No-reflow Phenomenon in PCI for STEMI
162 patients around the world
Available in Mexico
Instituto Nacional de Cardiologia Ignacio Chavez
1Research sites
162Patients around the world
This study is for people with
Coronary heart disease
Acute myocardial infarction
Requirements for the patient
To 85 Years
All Gender
Medical requirements
- Acute myocardial infarction with ST-segment elevation.Presentation to the institute within 12 hours of symptom onset.Coronary angioplasty chosen as the reperfusion treatment for the subject.Known diagnosis of diabetes or admission glucose >180 mg/dl.Informed consent signed.
- Hemodynamically unstable subjects.Subjects undergoing thrombolysis treatment in the current event.History of coronary revascularization surgery.Known allergy or hypersensitivity to Sodium-glucose co-transporter-2 (SGLT2) inhibitors.History of recurrent urinary tract infections.Known chronic kidney disease and estimated glomerular filtration rate (eGFR) < 20.Ongoing treatment with any SGLT2 inhibitor.Participation in another clinical trial or having participated in the week prior to recruitment.For women of childbearing age: Current or planned pregnancy or lactation.
Sites
Instituto Nacional de Cardiologia Ignacio Chavez
Recruiting
StudyEMPA-PCI
SponsorInstituto Nacional de Cardiologia Ignacio Chavez
Study typeInterventional
Conditions
Acute myocardial infarction
Requirements
To 85 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06342141
